EX-10.1
from 10-Q
9 pages
We Are Pleased to Offer You a Position With Sutro Biopharma, Inc. (The “Company”), as Chief Financial Officer, Reporting to Jane Chung, Chief Executive Officer, Effective 6/2/2025, or Such Earlier Date as May Be Mutually Agreed Between You and the Company. the Company Is Excited to Have You Join Our Exceptional Team and We Look Forward to a Purposeful and Productive Relationship. You Should Note That the Company May Modify Job Titles, Roles, Responsibilities, Salaries, and Benefits From Time to Time as It Deems Necessary. 1. Compensation 2. Equity A
12/34/56
EX-10.1
from 10-Q
76 pages
Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. Purchase and Sale Agreement Dated as of June 21, 2023 Between Sutro Biopharma, Inc. and Bxls V – Vault L.P
12/34/56
EX-10.2
from 10-Q
92 pages
Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. License and Collaboration Agreement by and Between Sutro Biopharma, Inc. and Astellas Pharma Inc. June 27, 2022 I
12/34/56
EX-10.29
from 10-K
64 pages
Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. License Agreement by and Between Sutro Biopharma, Inc. and Tasly Biopharmaceuticals Co., Ltd. December 20, 2021 License Agreement
12/34/56
